))
Trending News US – May 2, 2024
Manage episode 415990063 series 3046075
Contenu fourni par Vynamic. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Vynamic ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
In this episode, Mindy, Ryan, and Jen discuss recent newsworthy items, including the FDA approval of Rejoyn, the first prescription digital treatment for major depressive disorder. They also discuss the ongoing drug shortage crisis, as well as changes coming out of the Centers for Medicare & Medicaid Services and the impact those decisions will have over the next year.
Podcast Tags: healthcare, healthcare news, life sciences, health policy, public health, depression, mental health, digital treatment, drugs, pharmaceuticals, shortages, medications, FDA, CMS, Medicare Advantage, breakthrough technology, medical devices
Source Links:
- FDA clears first digital treatment for depression, but experts caution that research is still early
- Number of ongoing US drug shortages reaches new high, pharmacist group says
- FDA commissioner tells lawmakers his agency needs more authority to prevent drug shortages
- CMS final rule on broker comp, health equity could shake up Medicare Advantage
- Medicare official says breakthrough device reimbursement rule coming in early summer
Panel – Jen Burke, Mindy McGrath, Ryan Hummel
Research & Production – Anna Briccetti, Jen Burke
Recording & Editing – Mike Liberto, Rachel Skonecki
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
198 episodes
Partager
